HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Oncology·MeSH: Lymphoma
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| tipifarnib | Kura Oncology, Inc. (KURA) |
Frequently asked questions
How many drugs are in development for HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)?
BioSniper tracks 1 drug in development for HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) across 1 company.
How many clinical trials target HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)?
There are 1 clinical trial targeting HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) tracked by BioSniper.
Deep-dive into HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis